The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...

But the man’s condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

A 69-year-old man from Arizona tragically died after developing an aggressive form of cancer from a liver transplant, a rare ...

There’s a stigma surrounding liver cancer. Once you tell people you’ve got it, often you sense a slight judgment. “Oh”, you ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...